17 research outputs found
Factors associated with distress in patients with incurable cancer: addressing disparities at distinct healthcare system in Brazil
City Hope Comprehens Canc Ctr, Duarte, LA USAUniv Notre Dame, Notre Dame, IN 46556 USAUniv Fed São Paulo Unifesp, São Paulo, BrazilCity Hope Natl Med Ctr, Duarte, LA USADept Populat Sci, Duarte, LA USAUniv Fed São Paulo Unifesp, São Paulo, BrazilWeb of Scienc
Recommended from our members
Systemic therapy and COVID19: Immunotherapy and chemotherapy
As the novel severe acute respiratory syndrome coronavirus-2 related pandemic - Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not using life-saving treatments and the complexities related to the type of cancer itself, all must be taken into consideration before proceeding with treatment. Data from large registries such as COVID-19 and Cancer Consortium, Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) and NCI COVID-19 in Cancer Patients Study will hopefully provide granularity on the outcomes of patients with cancer who are infected with COVID-19. As these efforts are underway, this review aims to shed light on the management of patients with genitourinary malignancies being treated with systemic therapies while infected with COVID-19
Preliminary data on perceived cognitive function in Brazilian breast cancer survivors
City Hope Comprehens Canc Ctr, Duarte, CA USAUniv Fed São Paulo Unifesp, São Paulo, SP, BrazilUniv Fed São Paulo Unifesp, São Paulo, SP, BrazilWeb of Scienc
Emotional and physical late effect of testicular cancer treatment: Implications for follow-up
City Hope Comprehens Canc Ctr, Duarte, CA USAUniv Fed São Paulo Unifesp, São Paulo, SP, BrazilCity Hope Natl Med Ctr, Duarte, CA USAUniv Notre Dame, Notre Dame, IN 46556 USAUniv Fed São Paulo Unifesp, São Paulo, SP, BrazilWeb of Scienc
Is there a role for immunotherapy (IO) and tyrosine kinase inhibitors (TKI) for older adults with metastatic renal cell carcinoma (mRCC)?
Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC).
Recommended from our members
The HOLA COVID-19 Study: An International Effort to Determine How COVID-19 Has Impacted Oncology Practices in Latin America
Countries in Latin America and the Caribbean have become hotspots of the novel coronavirus (COVID-19) pandemic, exacerbating socioeconomic inequalities and overwhelming fragmented health systems. Studies from the United States and Europe have highlighted the disproportionate effects of COVID-19 on patients with cancer and the disruption it has caused on cancer care delivery. The HOLA COVID-19 Study aims to understand how cancer care in Latin American countries has been affected by the COVID-19 pandemic
Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the US National Cancer Database (NCDB)
Medeniyet Univ, Goztepe Training & Res Hosp, Internal Med, Istanbul, TurkeyCity Hope Natl Med Ctr, Med Oncol, Duarte, CA USACity Hope Natl Med Ctr, Biostat, Duarte, CA USAUniv Fed Sao Paulo, Med Oncol, Sao Paulo, BrazilUniv Alabama Birmingham Hosp, Urol, Birmingham, AL USAUniv Alabama Birmingham Hosp, Med Oncol, Birmingham, AL USAUniv Fed Sao Paulo, Med Oncol, Sao Paulo, BrazilWeb of Scienc
Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
Background The clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between PBRM1 mutations and response with immunotherapy (IO). We sought to determine genomic predictors of differential response to vascular endothelial growth factor–tyrosine kinase inhibitors (VEGF-TKIs) and IO.Methods Consecutive patients who underwent genomic profiling were identified; patients receiving either VEGF-TKIs or IO were included. Clinical tumor-normal whole exome sequencing and tumor whole transcriptome sequencing test were performed using a Clinical Laboratory Improvement Amendments (CLIA)-certified assay (Ashion Analytics; Phoenix, Arizona, USA). Genomic findings were compared between patients with clinical benefit (CB; complete/partial response or stable disease for >6 months) and no clinical benefit (NCB) in VEGF-TKI-treated patient cohort and IO-treated patient cohort.Results 91 patients received genomic profiling and 58 patients received VEGF-TKI and/or IO therapy. 17 received sequenced treatment involving both VEGF-TKI and IO, resulting in 32 patients in the IO cohort and 43 patients in the VEGF-TKI cohort. The most commonly used IO and VEGF-TKIs were nivolumab (66%) and sunitinib (40%). The most frequently detected alterations in the overall cohort were in VHL (64%), PBRM1 (38%), SETD2 (24%), KDM5C (17%) and TERT (12%). TERT promoter mutations were associated with NCB in the IO cohort (p=0.038); transcriptomic analysis revealed multiple differentially regulated pathways downstream of TERT. TERT promoter mutations and PBRM1 mutations were found to be mutually exclusive. While PBRM1 mutations were more prevalent in patients with CB with IO and VEGF-TKIs, no statistically significant association was found.Conclusions Our analysis found that TERT promoter mutations may be a negative predictor of outcome with IO and are mutually exclusive with PBRM1 loss-of-function mutations